Menu
ncarol.com
  • Home
  • Financial
  • Education
  • Business
  • Nyse
  • Finance
  • Yacht Buyer
  • Stocks
  • Health
ncarol.com

Electrically Altering Children's Brains: Psychiatry's Latest Treatment Fad
ncarol.com/10269470

Trending...
  • Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
  • Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
Electrically Altering Children's Brains
Mental health industry watchdog CCHR exposes new electroshock methods used in the $20 billion "ADHD" market—calls for a ban on all invasive electrical treatments

LOS ANGELES - ncarol.com -- Amid increasing worries about the potential for addiction with stimulant drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD), the Food and Drug Administration (FDA) has approved the Monarch eTNS System, an electrical stimulation device. This move has been criticized by the mental health industry watchdog Citizens Commission on Human Rights International, which argues that the device will only exacerbate concerns about interfering with children's brain development. A recent Gold Report underscores the controversy, noting that the FDA's approval was based on a limited four-week study involving just 31 children while acknowledging that "...the long-term effects of using" the device are unknown.[1]

"Years ago, the FDA demanded multiple trial results before approving drugs and devices. In recent years, the results of just two trials have generally been enough to satisfy federal regulators." However, with this latest device, "the FDA was happy with just one trial, even though only 31 children were exposed" to it, says The Gold Report.

According to CCHR, when invasive mental health treatment involves children, greater, not fewer clinical trials are needed—and more to the point, it says, it should never be considered in the first place. For electroconvulsive therapy (shock treatment or ECT), there are no clinical trials proving safety and efficacy. The external trigeminal nerve stimulation (eTNS) is not ECT but it is based on the same unproven theory that a non-physical "disorder" can be corrected by an electrical assault on the brain, CCHR adds.

About the size of a cell phone, the eTNS connects to a disposable patch placed on a child's forehead at bedtime. Once turned on, the device sends low stimulating pulses to the trigeminal nerve—the body's thickest nerve—through the patch overnight. The nerve's branches are located close to the skin's surface, just above the eyebrows. It's approved for children ages 7-12. The most common side effects to date are drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue.[2]

More on ncarol.com
  • $317M Revenue and a Clear Path to $1B: $IQST is Positioned for a Major Profitability Inflection
  • ASI Hosts 2026 Executive Business Summit for Global Partner Community
  • US Interest Rate Pivot: Hedge Funds Leverage Tickeron AI for 177% Annualized Return
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory

However, CCHR says there's no long-term studies that determine the effects of sending continuous electrical pulses through a child's brain every night.

The industry behind ADHD thrives on the fact that an ADHD diagnosis is based solely on behavioral assessments, with no medical tests to confirm it as a biological condition requiring treatment. No brain scan can determine the existence of ADHD.[3] The psychiatric drugs prescribed to treat it are linked to psychosis, addiction, cardiac arrest and suicide and rake in $20 billion a year in U.S. sales alone.[4]

The eTNS adds to this lucrative market. The pulse emitter alone costs $1,000 and a month's supply of patches costs $100. According to another report, the broader field of wearable technology is forecast to become a huge $291 billion industry by 2030, with healthcare identified as a key market for wearable devices.[5]

The FDA trial summary said that some trial volunteers were invited to continue treatment for an entire year. However, most of them dropped out way before the year was up. In fact, only 18 children were still in the trial at 3 months. By 6 months, 10 had dropped out. At 9 months, there were just 6 children left. At 12 months, only 3 children were left using eTNS. The Gold Report rightly questions: "If eTNS was so effective (not to mention safe), why did 15 out of 18 children stop using it?"

For three children, some of the results had to be omitted "due to excessive movement artifact." "In plain language, what this means is that the kids moved around too much in their sleep, which affected the accuracy of the readings," according to the Gold Report article. There were likely serious adverse events, which were not listed, other than the researchers decided that the device was not responsible for them.[6]

Experts remain highly critical of the ongoing biological model of "mental disorder" that is relied upon. Australian psychiatrist, Niall McLaren, writes, "Psychiatry's headlong rush to be 'more biological than thou' is partly because they have no theory of mind and don't know where to start…."[7] Psychiatrists say "'Mental disorder is brain disorder,' but that is an ideological claim, not a scientific statement."[8]

More on ncarol.com
  • Craigory Dunn & Dre Barracks Release Gospel-Soul Collaboration The Soul Renaissance
  • Why Screen-Fatigued Parents are Choosing the Human Bridge
  • Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
  • Peccioli Becomes New Orleans: In July 2026, the magic of jazz comes to Tuscany
  • Luxur Tequila Introduces a New Standard of Luxury Spirits with Customizable Bottles & Visionary Lea

Pediatric neurologist, the late Dr. Fred Baughman, author of The ADHD Fraud: How Psychiatry Makes Patients Out of Normal Children said making children "believe they have something wrong with their brains that makes it impossible for them to control themselves without a pill"[9]—or in this case electricity—does them a great disservice. Labeling children's "unwanted" behavior as a brain disease or mental disorder is based on "pure speculation with never a shred of scientific evidence to back it up."[10] Parents, he said, are deceived and misled.

CCHR is unwavering in its stance that all forms of electrical "treatment" for behavioral or learning disabilities must be outlawed, particularly when it comes to vulnerable children. The approval of the latest electrical stimulation device, despite its lack of long-term safety data, is seen as a dangerous precedent that prioritizes profit over the well-being of young patients. CCHR argues that the mental health industry's reliance on invasive interventions like electrical stimulation is not only scientifically unfounded but also ethically indefensible.

CCHR, established in 1969 by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz, remains committed to exposing and challenging the psychiatric industry's profit-driven practices. Their call to action is clear: children's minds and futures should not be subjected to experimental and invasive treatments in the name of mental health.

Sources:

[1] Y. Rabinovitz, "From Ritalin to brain implants: How the FDA is fast-tracking the devices of the future," The Gold Report, 2 Aug 2024, www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future

[2] neurosigma.com/

[3] www.cchrint.org/2023/04/05/millions-adhd-drugs-without-knowing-side-effects/

[4] www.cchrint.org/2022/10/07/cchr-warns-children-labeled-adhd/

[5] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future

[6] www.thegoldreport.com/news/from-ritalin-to-brain-implants-how-the-fda-is-fast-tracking-the-devices-of-the-future

[7] "Is There Room for a Human Spirit?" Niall McLaren on Critical Psychiatry, 30 July 2024

[8] "Last Mention of ADHD for the year," Niall McLaren on Critical Psychiatry, 21 Nov. 2023

[9] Fred A. Baughman, Jr., MD, "Treatment of Attention-Deficit Hyperactivity Disorder," Journal of the American Medical Association, Vol. 269, No. 18, 12 May 1993, p. 2369

[10] www.cchrint.org/2022/10/28/cchr-launches-investigation-into-educational-decline/

Contact
Citizens Commission on Human Rights International
***@cchr.org


Source: Citizens Commission on Human Rights

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • The Franchise King® Releases Free Guide for Nervous Buyers
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
  • Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples
  • Matthew Sisneros Releases Raw and Unfiltered Memoir: The Devil Lost Another One — A Powerful Story of Crime, Consequence, and Redemption
  • From Life to Light: Jess L. Martinez Shares a Soulful Poetry Collection That Explores What It Means to Be Human
  • Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
  • Cleveland County Families Choosing to Restore Quality Furniture Instead of Buying New
  • Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
  • 46th International Symposium On Forecasting – Dates, Venue And Speakers Announced
  • Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
  • Bonavita Luxury & Portable Lavatories Announces Rebrand to Bonavita Site Solutions
  • Raleigh Emerges as a Key Player in Sustainable Fashion Innovation for 2026
  • Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
_catLbl0 _catLbl1

Popular on ncarol.com

  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies - 127
  • Still Using Ice? FrostSkin Reinvents Hydration - 113
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP

Similar on ncarol.com

  • Hypnotherapy Finder Announces Official US Wide Launch After Successful Soft Launch
  • Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
  • Why Screen-Fatigued Parents are Choosing the Human Bridge
  • Local Eco-Friendly Cleaning Company Expands Services to Cary, Apex, and Morrisville
  • Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
  • RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
  • Grads aren't getting hired — here's what we're doing about it
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute